Antibodies, Neutralizing
- Name
- Antibodies, Neutralizing
- Accession Number
- DBCAT005596
- Description
Antibodies that reduce or abolish some biological activity of a soluble antigen or infectious agent, usually a virus.
- Drugs
Drug Drug Description Patritumab Patritumab has been used in trials studying the treatment of LUNG CANCER, Solid Tumors, Neoplasms by Site, Head and Neck Neoplasms, and Non-small Cell Lung Cancer, among others. Fletikumab Fletikumab is under investigation in clinical trial NCT01038674 (Safety and Tolerability of Anti-IL-20 in Subjects With Rheumatoid Arthritis). Dusigitumab Dusigitumab has been used in trials studying the treatment of Cancer, Advanced Solid Malignancies, Unresectable or Metastatic Hepatocellular Carcinoma (HCC), and Hormone-sensitive, HER-2 Negative Metastatic Breast Cancer. Carlumab Carlumab has been used in trials studying the treatment of Cancer and Prostate Cancer. Bezlotoxumab A monoclonal antibody used to reduce the recurrence of Clostridium difficile infections. Suvratoxumab Suvratoxumab is under investigation in clinical trial NCT02296320 (Study of the Efficacy and Safety of MEDI4893). Actoxumab Actoxumab is under investigation in clinical trial NCT01241552 (A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)). Bentracimab Bentracimab is under investigation in clinical trial NCT04286438 (Bentracimab (PB2452) in Ticagrelor-treated Patients With Uncontrolled Major or Life-threatening Bleeding or Requiring Urgent Surgery or Invasive Procedure). AVP-21D9 AVP-21D9 is a fully human anthrax monoclonal antibody that is being investigated as an anthrax antitoxin. - Drugs & Drug Targets
Drug Target Type Bezlotoxumab Clostridium difficile Toxin B target